NEOPHAM 6.4% Drug Patent Profile
✉ Email this page to a colleague
When do Neopham 6.4% patents expire, and what generic alternatives are available?
Neopham 6.4% is a drug marketed by Hospira and is included in one NDA.
The generic ingredient in NEOPHAM 6.4% is amino acids. There are three hundred and fifty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the amino acids profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Neopham 6.4%
A generic version of NEOPHAM 6.4% was approved as amino acids by B BRAUN on April 13th, 2012.
Summary for NEOPHAM 6.4%
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NEOPHAM 6.4% at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for NEOPHAM 6.4%
US Patents and Regulatory Information for NEOPHAM 6.4%
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospira | NEOPHAM 6.4% | amino acids | INJECTABLE;INJECTION | 018792-001 | Jan 17, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |